Kalaris Therapeutics announced encouraging additional data from its Phase 1a single ascending dose trial of TH103 in neovascular age-related macular degeneration. The expanded dataset included 17 treatment-naive patients and 3 treatment-experienced patients, all completing six months of follow-up, and showed robust improvements in vision and retinal anatomy. Pharmacokinetic data indicated 27- to 53-fold lower plasma Cmax compared to leading anti-VEGF agents, suggesting greater intraocular retention, with 41% of treatment-naïve patients requiring retreatment at 4 months or later, 35% at 5 months or later, and 29% needing no additional anti-VEGF therapy during the six-month follow-up. Treatment-experienced patients saw an average two-month extension in retreatment intervals compared with prior therapies. No cases of intraocular inflammation were observed at the 2.5 mg dose following manufacturing process adjustments, while one patient at the 5 mg dose experienced transient intraocular inflammation that resolved without sequelae.
Kalaris Therapeutics, Inc.Positive Phase 1a results for TH103 show improved vision and retinal anatomy, with favorable pharmacokinetics and safety.
Advanced Micro Devices Inc